Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aromatase inhibitors in the breast cancer clinic: focus on exemestane.
Van Asten K, Neven P, Lintermans A, Wildiers H, Paridaens R. Van Asten K, et al. Among authors: lintermans a. Endocr Relat Cancer. 2014 Jan 16;21(1):R31-49. doi: 10.1530/ERC-13-0269. Print 2014 Feb. Endocr Relat Cancer. 2014. PMID: 24434719 Review.
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A, Vanderschueren D, Verhaeghe J, Van Asten K, Jans I, Van Herck E, Laenen A, Paridaens R, Billen J, Pauwels S, Vermeersch P, Wildiers H, Christiaens MR, Neven P. Lintermans A, et al. Eur J Cancer. 2014 Nov;50(17):2925-31. doi: 10.1016/j.ejca.2014.08.012. Epub 2014 Oct 7. Eur J Cancer. 2014. PMID: 25304297
Safety of aromatase inhibitor therapy in breast cancer.
Lintermans A, Neven P. Lintermans A, et al. Expert Opin Drug Saf. 2015 Aug;14(8):1201-11. doi: 10.1517/14740338.2015.1053458. Epub 2015 Jun 9. Expert Opin Drug Saf. 2015. PMID: 26059833 Review.
Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial.
Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné AS, Brouckaert O, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Vuylsteke P, Wynendaele W, Casteels M, Van Huffel S, Lybaert W, Van Ginderachter J, Paridaens R, Vergote I, Dezentjé VO, Van Calster B, Guchelaar HJ. Neven P, et al. Among authors: lintermans a. Clin Cancer Res. 2018 May 15;24(10):2312-2318. doi: 10.1158/1078-0432.CCR-17-3028. Epub 2018 Feb 19. Clin Cancer Res. 2018. PMID: 29459457 Clinical Trial.
A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, Verhaeghe J, Vanderschueren D, Smeets A, Van Limbergen E, Leunen K, Christiaens MR, Neven P. Lintermans A, et al. Breast Cancer Res Treat. 2014 Jul;146(1):109-16. doi: 10.1007/s10549-014-2986-7. Epub 2014 May 11. Breast Cancer Res Treat. 2014. PMID: 24816806
Drug safety evaluation of exemestane.
Lintermans A, Neven P, Paridaens R. Lintermans A, et al. Expert Opin Drug Saf. 2011 May;10(3):473-87. doi: 10.1517/14740338.2011.567264. Epub 2011 Mar 24. Expert Opin Drug Saf. 2011. PMID: 21428848 Review.
Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.
Lintermans A, Laenen A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonné AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P. Lintermans A, et al. Ann Oncol. 2013 Feb;24(2):350-355. doi: 10.1093/annonc/mds290. Epub 2012 Oct 4. Ann Oncol. 2013. PMID: 23038762 Free article.
20 results